Abstract
A bio-anatomical quality assurance (QA) method employing tumor control probability (TCP) and normal tissue complication probability (NTCP) is described that can integrate radiobiological effects into intensity-modulated radiation therapy (IMRT). We evaluated the variations in the radiobiological effects caused by random errors (r-errors) and systematic errors (s-errors) by evaluating TCP and NTCP in two groups: patients with an intact prostate (Gintact) and those who have undergone prostatectomy (Gtectomy). The r-errors were generated using an isocenter shift of ±1 mm to simulate a misaligned patient set-up. The s-errors were generated using individual leaves that were displaced inwardly and outwardly by 1 mm on multileaf collimator field files. Subvolume-based TCP and NTCP were visualized on computed tomography (CT) images to determine the radiobiological effects on the principal structures. The bio-anatomical QA using the TCP and NTCP maps differentiated the critical radiobiological effects on specific volumes, particularly at the anterior rectal walls and planning target volumes. The s-errors showed a TCP variation of –40–25% in Gtectomy and –30–10% in Gintact, while the r-errors were less than 1.5% in both groups. The r-errors for the rectum and bladder showed higher NTCP variations at ±20% and ±10%, respectively, and the s-errors were greater than ±65% for both. This bio-anatomical method, as a patient-specific IMRT QA, can provide distinct indications of clinically significant radiobiological effects beyond the minimization of probable physical dose errors in phantoms.
Keywords: Bio-anatomical quality assurance, tumor control probability, normal tissue complication probability, intensity-modulated radiation therapy, prostate cancer
INTRODUCTION
From a physical perspective, the aim of conventional quality assurance (QA) methods that measure a delivered dose to a phantom is to verify probable physical dose errors. However, the typical QA methods do not allow for specific positions in the actual patient anatomy where the dose errors are detected. Because of this, it is difficult to determine the clinically significant radiobiological impacts on the planning target volume (PTV) and the organs at risk (OAR). A new inverse verification QA method based on dynalog files has been developed to verify the dosimetric effects of intensity-modulated radiation therapy (IMRT) using the multileaf collimator (MLC) [1–8]. This practical approach facilitates evaluation of dose errors on CT images. However, it remains difficult to intuitively determine the ultimate radiobiological effects on patient anatomy beyond that of a generic physical evaluation on a whole volume of principal structures.
In this study, we have developed a radiobiological model-based bio-anatomical QA method using tumor control probability (TCP) and normal tissue complication probability (NTCP) to provide an improved and practical, patient-specific QA for IMRT. The radiobiological evaluation of dose error with inverse verification QA was implemented on actual patient anatomy. The subvolume-based TCP and NTCP were visualized on CT images to detect clinically significant errors on specific volumes.
MATERIALS AND METHODS
IMRT plan simulations: intact and prostatectomy cases
Prostate cancer patients scheduled to undergo IMRT were divided into two groups based on whether a prostatectomy had been performed (Gtectomy) or not (Gintact). The parameters and beam delivery techniques for the initial IMRT plans (MLCref) are summarized in Table 1 [9]. Plans were made for evaluating the dosimetric effects caused by using the Millennium 120 leaf-MLC (Varian Medical System, Palo Alto, CA, USA) to simulate patient set-up misalignments. The influence of systematic errors (s-errors) pertaining to the MLC were analyzed using reconstructed MLC field files. Reloading MLC files to replace the reference field files in the planning system, Eclipse (v. 7.3.1, Varian Medical System) enabled evaluation of the dosimetric effects by several s-errors.
Table 1.
Patients | Beam delivery | Prescription | CTVa-to-PTVb margin | Internal immobilization |
---|---|---|---|---|
Intact prostate (Gintact) | 15 MV photon beams 5 fields (200°, 270°, 340°, 60°, 120°), Step-and-shoot | 70 Gy, 35 fr.c | CTV (including seminal vesicle) + 10 mm, but 5 mm for posterior wall of the prostate | Rectal balloons filled with 70 cm3 air |
Prostatectomy (Gtectomy) | 15 MV photon beams 7 fields (220°, 260°, 310°, 0°, 50°, 100°, 140°), Step-and-shoot | 78 Gy, 39 fr. | CTV + 10 mm, but 5 mm for posterior wall of the prostate | Rectal balloons filled with 70 cm3 air |
aCTV: clinical target volume; bPTV: planning target volume; cfr.: fractions.
A plan using MLC files converted from dynalog files was used as a reference plan (DLGref) and included the unavoidable operation error of the MLC. This method used inverse IMRT QA to determine dose differences resulting from MLC leaf misalignment. To evaluate the effects due to MLC s-errors, the positions of all of the individual leaves were shifted by as much as ±1 mm in the MLC field files [10–12]. The modified fields were obtained by changing the positions of the inward and outward MLC leaves in each bank. The enlarged field (MLC+1+1) was configured by the outward displacement of the leaves (moving the leaves in each left and right bank out of the beam's eye view), while the shrunken field (MLC−1−1) was configured by the inward displacement of the leaves (moving the leaves inwards within the beam's eye view). If any pairs of leaves that were laid on the same line collided as they moved toward the center of the field, they were left in their original position while new positions were assigned for the rest of the leaves in the MLC files.
The converted MLC field files were reconstructed using the same principle as in a previous study [2]. The developed software was modified using MATLAB (v. 7.10.0.499, The MathWorks, Natick, MA, USA) to export the files for use in simulating s-errors.
The effects of treatment room set-up errors were studied using an isocenter shift of ±1 mm along the X- and Y-orthogonal axes (diagonally ∼1.41 mm) in the axial section. The random errors (r-errors) were simulated based on several combinations of movements along the orthogonal axis in the plane. The simulated plans were denoted as DLGm1,m2 where ‘m1’ represents distance along the X-axis and ‘m2’ represents the Y-orthogonal axis. Dose errors in four plans (DLG+1+1, DLG+1−1, DLG−1+1, and DLG−1−1) were analyzed with bio-physical evaluation methods [13, 14].
Plan evaluation based on bio-physical indices
After the plan simulations of s- and r-errors were completed, the results were evaluated using various physical and radiobiological indices. The variables of each equation are listed and explained in Table 2. For physical evaluation, the improved homogeneity index (sindex) [15] was calculated to determine the uniformity of the delivered dose, and the conformity number (CN) was calculated to describe dose conformity [eq. (1) and eq. (2)] [16]:
(1) |
(2) |
Table 2.
Parameters | Definition | Equations |
---|---|---|
Di | Delivered dose to the i-th voxel | (1) |
vi | Corresponding volume of i-th voxel | |
Dp | Prescribed dose | |
VT | Total target volume | (1), (2) |
VRI | Corresponding volume to the reference isodose | (2) |
VT,RI | Target volume covered by the reference isodose | |
n | Total fraction number | (3) |
di | Delivered fractional dose on i-th individual voxel | |
df | Reference dose per fraction | |
α/β | The parameter of a linear quadratic model | |
R | The region composed of i-th subvolumes | (5), (6) |
γ50 | The normalized slope at the 50% tumor control probability | |
TCD50 | Dose required to achieve 50% tumor control probability | (5) |
TD50 (veff) | The tolerance dose corresponding to the veff to reach the 50% normal tissue complication probability | (6) |
veff | Effective volume |
The gamma variation was calculated using 3 mm distance-to-agreement and a 3% dose difference for evaluated dose matrixes obtained in several error simulations, for comparison with the reference dose matrix in DLGref [17].
In this study, the equivalent uniform dose (EUD) is classified as a physical index, because identical radiobiological parameters are applied to each volume for each organ. The target and OAR EUDs were calculated based on the standard effective dose (SEDi): using eq. (3) [18]. The generalized equivalent uniform dose (gEUD) in eq. (4) [19] was determined by inserting the SEDi [20].
(3) |
(4) |
To analyze radiobiological effects, TCP and NTCP were calculated using the specific organ value ‘a', the radio-sensitivities of each organ, and the tolerance doses (all shown in Table 3) [21–28]. Most of these radiobiological values originated from the experimental research of Emami and Burman [22, 26], although several were collected from a recent clinical study [21, 24, 25, 28]. Tumor control probability and NTCP based on the phenomenological logistic model [eq. (5) and eq. (6)] were evaluated as follows [29–31]:
(5) |
(6) |
Table 3.
Type | Organs | a | γ50 | TCD 50a / TD50b | α/β (endpoint) |
---|---|---|---|---|---|
Tumor | Prostate | –13 | 2.2 | 67.5 | 1.5 (local control) |
Critical structures | Rectum | 8.33 | 2.66 | 80 | 5.4 (rectal bleeding) |
Bladder | 2 | 3.63 | 80 | 7.5 (cystitis) |
aTCD50: The dose required for 50% probability of tumor control; bTD50: The tolerance dose corresponding to 50% complication probability of normal tissues.
Here, we assume that the individual γ50 on corresponding subvolumes of the PTV or OAR are the same depending on the structure.
To visualize the radiobiological effects at specific anatomical positions, the subvolume-based TCP and NTCP were overlaid on CT images [32]. The overall bio-anatomical QA was completed using the procedures shown in Fig. 1. After the exported dose files for each plan simulation were interpolated to adjust the resolution of the CT images, the corresponding doses on the volume of each principal structure were extracted using the contour coordinates in the structure files. The calculated TCPi and NTCPi values from the exported dose matrices were overlapped on CT images to visualize the radiobiological effects on patient anatomical coordinates. Three different color maps assisted in visualizing the TCP and NTCP on these images (Fig. 2 and Fig. 3). When the simultaneous mapping of TCP and NTCP values was required on the overlapped volume in the axial view, the order of priority was set as the rectum, the PTV and then the bladder. .
RESULTS
By implementing the radiobiological model-based bio-anatomical QA method, the anatomy-based radiobiological evaluation was able to determine the dosimetric impacts on the principal structures. This method detected greater NTCP variations in the r-error simulations as compared with physical IMRT QA. Tumor control probability and NTCP variations of the s-errors were distinctly discriminated in both patient groups.
Physical perspective
Equivalent uniform dose variations caused by r-errors or MLC s-errors in the DLGref were less than 1.5% on the PTV. The s-errors resulted in symmetrical EUD variations on the PTV and the bladder that were as high as ±15% and ±13%, respectively, in both patient groups. However, EUD of the rectum in Gintact patients was higher at ±15% than that of Gtectomy patients at ±11%. The MLC+1+1 s-errors had more than twice the inferior Sindex. The MLC−1−1 simulations showed an improved Sindex with a delivered dose that was relatively lower but still close to the prescribed one. However, the dose distribution in the MLC−1−1 field produced a decrease in CN below 0.5.
The s-errors showed decreased gamma pass ratios, from a minimum of 10% and 22% to a maximum of 40% in Gintact and Gtectomy patients, respectively, while r-errors were average 5–6% in both groups. Most of the dose differences induced by r-errors were observed in the regions alongside or opposite the direction of the isocenter displacement. The beamlets passing the field boundary yielded higher gamma indices on the peripheral regions of structures. The gamma distribution provided a relatively large variation in simulated errors as well as in the rough estimation of the sketch region where the physical dosimetric errors occurred. However, the expected radiobiological impacts caused by the physical dose errors could not be evaluated on the principal structures.
Radiobiological perspective
The TCP and NTCP analyses combined with physical evaluation enabled the differentiation of critical dosimetric errors. The s-errors caused the highest TCP variations, ranging from –42–25% in Gtectomy patients and from –28–10% in Gintact, whereas the maximum r-error variation was 1.5% (Table 4). Tumor control probability variation in the MLC−1−1 field, which reached ±15%, was more than twice that of the symmetric difference of EUD.
Table 4.
TCP of prostatectomy patients (Gtectomy) (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Patient/Simulation | A | B | C | D | E | F | G | H | |
r-errors | DLGref | 71.61 | 67.49 | 70.56 | 71.58 | 71.63 | 71.20 | 72.53 | 72.48 |
DLG+1+1 | 71.71 | 67.52 | 69.99 | 71.52 | 71.23 | 71.14 | 72.14 | 72.46 | |
DLG+1–1 | 71.17 | 67.06 | 70.40 | 67.06 | 71.26 | 70.87 | 72.26 | 71.91 | |
DLG−1+1 | 71.62 | 67.47 | 69.88 | 71.59 | 71.28 | 71.18 | 72.27 | 72.53 | |
DLG−1–1 | 71.02 | 67.05 | 70.30 | 71.14 | 71.55 | 70.92 | 72.42 | 71.94 | |
Maximum variationa | –0.82 | –0.65 | –0.96 | –6.31 | –0.56 | –0.46 | –0.54 | –0.79 | |
0.15 | 0.047 | –0.23 | 0.01 | –0.12 | –0.031 | –0.16 | 0.061 | ||
s-errors | MLC−1–1 | 47.44 | 44.69 | 40.67 | 48.75 | 47.89 | 45.31 | 42.23 | 45.77 |
MLC+1+1 | 85.67 | 82.74 | 87.94 | 85.22 | 85.73 | 86.63 | 89.08 | 87.76 | |
Maximum variation | –33.75 | –33.78 | –42.37 | –31.89 | –33.14 | –36.36 | –41.78 | –36.86 | |
19.64 | 22.60 | 24.64 | 19.05 | 19.68 | 21.68 | 22.81 | 21.08 | ||
TCP of intact prostate patients (Gintact) (%) | |||||||||
Patient/simulation | I | J | K | L | M | ||||
r-errors | DLGref | 88.88 | 83.20 | 87.22 | 86.87 | 87.50 | |||
DLG+1+1 | 88.96 | 83.29 | 87.20 | 86.87 | 87.51 | ||||
DLG+1–1 | 88.32 | 82.79 | 87.13 | 86.70 | 87.08 | ||||
DLG−1+1 | 88.99 | 83.25 | 87.11 | 86.85 | 87.52 | ||||
DLG−1–1 | 88.30 | 82.72 | 87.05 | 86.67 | 87.05 | ||||
Maximum variation | 0.13 | 0.11 | –0.024 | –0.0061 | 0.02 | ||||
–0.65 | –0.57 | –0.20 | –0.23 | –0.52 | |||||
s-errors | MLC−1–1 | 68.66 | 77.07 | 77.87 | 62.75 | 70.25 | |||
MLC+1+1 | 96.12 | 87.76 | 92.02 | 95.70 | 94.57 | ||||
Maximum variation | –22.75 | –7.37 | –10.72 | –27.77 | –19.72 | ||||
8.15 | 5.48 | 5.50 | 10.16 | 8.08 |
aMaximum variation: maximum error that is negative and positive difference.
The NTCPs of the rectum for r- and s-errors were double in Gintact patients than in Gtectomy patients. The MLC+1+1 s-errors increased the NTCP values of the rectum to a maximum of 28% among Gintact, whereas NTCP was below 11% in the DLGref plan (Table 5). Normal tissue complication probability variation of the bladder for r-errors was less than 10% in Gtectomy. However, higher doses were delivered to each subvolume with simulated s-errors, resulting in a maximum three-fold increase in NTCP variation of the bladder compared with that of Gintact (Table 6).
Table 5.
NTCP of prostatectomy patients (Gtectomy) – rectum (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Patient/simulation | A | B | C | D | E | F | G | H | |
r-errors | DLGref | 2.64 | 4.40 | 4.44 | 4.81 | 5.54 | 5.01 | 6.23 | 5.98 |
DLG+1+1 | 3.26 | 4.88 | 5.27 | 5.30 | 6.77 | 5.82 | 6.84 | 6.48 | |
DLG+1–1 | 2.34 | 3.74 | 4.05 | 3.74 | 5.19 | 4.56 | 5.56 | 5.10 | |
DLG−1+1 | 3.17 | 4.79 | 5.22 | 5.31 | 6.72 | 5.83 | 6.92 | 6.50 | |
DLG−1–1 | 2.25 | 3.72 | 4.02 | 4.12 | 5.14 | 4.57 | 5.62 | 5.13 | |
Maximum variationa | –14.70 | –15.60 | –9.46 | –22.15 | –7.08 | –8.86 | –10.84 | –14.64 | |
23.76 | 10.82 | 18.71 | 10.38 | 22.39 | 16.46 | 11.04 | 8.81 | ||
s-errors | MLC−1-1 | 0.89 | 1.70 | 1.38 | 1.89 | 2.16 | 1.80 | 2.17 | 2.06 |
MLC+1+1 | 5.79 | 9.26 | 10.69 | 9.51 | 11.49 | 10.92 | 14.82 | 12.93 | |
Maximum variation | –66.09 | –61.36 | –68.81 | –60.62 | –61.03 | –64.07 | –65.16 | –65.54 | |
119.88 | 110.14 | 140.78 | 97.88 | 107.59 | 118.15 | 137.79 | 116.32 | ||
NTCP of intact prostate patients (Gintact) – rectum (%) | |||||||||
Patient/Simulation | I | J | K | L | M | ||||
r-errors | DLGref | 8.37 | 7.40 | 15.03 | 11.90 | 15.38 | |||
DLG+1+1 | 9.07 | 8.17 | 16.75 | 14.16 | 16.49 | ||||
DLG+1–1 | 6.40 | 5.89 | 13.86 | 10.99 | 13.05 | ||||
DLG−1+1 | 9.07 | 5.76 | 16.74 | 13.98 | 16.19 | ||||
DLG−1–1 | 6.57 | 5.76 | 13.86 | 10.83 | 12.76 | ||||
Maximum variation | –23.51 | –22.11 | –7.82 | –8.96 | –17.03 | ||||
8.46 | 10.38 | 11.37 | 19.01 | 7.21 | |||||
s-errors | MLC−1–1 | 2.20 | 4.81 | 8.32 | 3.48 | 5.68 | |||
MLC+1+1 | 19.60 | 10.86 | 21.90 | 25.21 | 27.87 | ||||
Maximum variation | –73.74 | –35.03 | –44.66 | –70.77 | –63.05 | ||||
134.28 | 46.73 | 45.65 | 111.86 | 81.17 |
aMaximum variation: maximum error that is negative and positive difference.
Table 6.
NTCP of prostatectomy patients (Gtectomy) – bladder (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Patient/simulation | A | B | C | D | E | F | G | H | |
r-errors | DLGref | 3.87 | 3.44 | 7.74 | 4.78 | 3.87 | 2.98 | 8.11 | 3.03 |
DLG+1+1 | 3.69 | 3.32 | 7.22 | 4.62 | 3.52 | 2.81 | 7.57 | 2.93 | |
DLG+1–1 | 3.99 | 3.64 | 8.03 | 5.07 | 3.99 | 3.08 | 8.81 | 3.20 | |
DLG−1+1 | 3.69 | 3.35 | 7.17 | 4.59 | 3.51 | 2.84 | 7.72 | 2.92 | |
DLG−1–1 | 3.99 | 3.67 | 7.99 | 5.05 | 4.02 | 3.12 | 8.91 | 3.20 | |
Maximum variation | –4.81 | –3.47 | –7.45 | –3.96 | –9.31 | –5.67 | –6.63 | –3.35 | |
3.13 | 6.67 | 3.72 | 6.09 | 4.01 | 4.64 | 9.77 | 5.89 | ||
s-errors | MLC−1–1 | 1.38 | 1.18 | 2.05 | 1.75 | 1.27 | 0.86 | 1.95 | 0.84 |
MLC+1+1 | 8.32 | 8.31 | 21.90 | 10.69 | 9.71 | 8.01 | 25.02 | 8.32 | |
Maximum variation | –64.35 | –65.75 | –73.55 | –63.36 | –67.09 | –71.13 | –75.92 | –72.29 | |
114.98 | 141.14 | 182.76 | 123.81 | 151.24 | 168.79 | 208.38 | 175.10 | ||
NTCP of intact prostate patients (Gintact) – bladder (%) | |||||||||
Patient/simulation | I | J | K | L | M | ||||
r-errors | DLGref | 16.98 | 6.77 | 14.27 | 28.81 | 9.06 | |||
DLG+1+1 | 16.56 | 6.45 | 13.86 | 27.71 | 8.81 | ||||
DLG+1–1 | 18.00 | 7.28 | 14.57 | 29.10 | 9.46 | ||||
DLG−1+1 | 16.54 | 6.50 | 13.82 | 27.99 | 8.90 | ||||
DLG−1–1 | 18.02 | 7.34 | 14.53 | 29.40 | 9.55 | ||||
Maximum variation | –2.56 | –4.75 | –3.12 | –3.82 | −2.69 | ||||
6.16 | 8.35 | 2.09 | 2.05 | 5.47 | |||||
s-errors | MLC−1–1 | 5.44 | 4.87 | 8.98 | 9.57 | 3.73 | |||
MLC+1+1 | 32.70 | 8.98 | 19.85 | 54.03 | 14.04 | ||||
Maximum variation | –67.97 | –28.03 | –37.06 | –66.78 | −58.86 | ||||
92.62 | 32.66 | 39.14 | 87.52 | 54.98 |
aMaximum variation: maximum error that is negative and positive difference.
The visualized TCP and NTCP mappings on CT images demonstrated the radiobiological effects on the anatomical structure of individual patients (Figs 2 and 3). The organ-based radiobiological effects caused by r- and s-errors were easily distinguishable on the visible organ contours. Partial volumes showing lower TCP and higher NTCP values than those of the surrounding subvolumes were easily differentiated, even when the TCP and NTCP values of the whole volume were relatively low.
By applying the bio-anatomical QA method, we were able to detect the primary differences in the radiobiological effects between the MLC+1+1 and MLC−1−1 fields. Higher values and large variations for NTCP of the rectum were observed on overlapping volumes between the PTV and the rectum and peripheral regions on the anterior rectal wall. In one patient in the Gintact group, the overall rectum complication was 28% in the MLC+1+1 field, while some voxels on the anterior rectal wall showed increased NTCP levels of up to 85% (Fig. 2d). Subvolume-based NTCP can be evaluated using CT images combined with the generic NTCP of the total volume of the rectum. The difference in radiobiological effects on the TCP and NTCP maps were referenced (Fig. 2f) to detect the primary subvolumes influenced by the induced errors.
DISCUSSION
Phantom-based dose measurements and QA have been the fundamental methods for verifying IMRT doses. However, the bio-anatomical QA method we have presented shows distinct radiobiological impacts that cannot be evaluated with physical QA alone. This QA method determines the radiobiological factor that needs to be focused on to detect clinically significant dosimetric effects, beyond simply minimizing the physical dose error. Although an ideal TCP and NTCP model could not be provided owing to incomplete knowledge of the radiobiological parameters, it is increasingly important to integrate such factors into clinical dosimetric evaluation [33].
The TCP and NTCP mappings on CT images were useful for intuitively determining the eventual organ-based radiobiological impact of the delivered dose on a particular anatomical position. Analysis of TCP and NTCP differences at specific positions (Fig. 2f and Fig. 3f) can contribute to a re-optimization of the treatment plan during a fractionated treatment course. This method could be made available for other sites of IMRT, besides those included in this study, using the appropriate radiobiological parameters and any type of medical image.
Recent studies have suggested that analytic results predict rectum toxicity according to the organ type with different endpoints; the rectum can be regarded as a serial organ in the case of rectal bleeding or as a parallel organ in the case of fecal incontinence [34, 35]. New scientific research has begun to replace old radiobiological data that are no longer appropriate for application with current techniques [33]. Several limitations of radiobiological evaluation have been noted, but the importance of the TCP and NTCP models and their application feasibility are still emphasized [36, 37]. If appropriate parameters can be substituted for the older ones we used in the current study, successful application of the TCP and NTCP models would be expected.
Bio-anatomical QA can also be used to predict radiobiological effects before treatment. Such an approach integrated with radiobiological evaluation could be applied as a complementary IMRT QA method, especially for other sites requiring a high gradient dose distribution while sparing OAR.
In conclusion, the radiobiological model-based bio-anatomical QA showed more distinct TCP and NTCP variations for r- and s-errors. The visualization of subvolume-based TCP and NTCP on CT images can be used to detect clinically significant dosimetric errors on principal structures in patient-specific IMRT. This QA approach can provide a useful and practical dosimetric verification method when integrated with inverse IMRT QA and can overcome limitations of physical QA methods.
FUNDING
This work was supported by the 3N Researcher Support Program; and the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) (2010-0017479 and 2009-00420).
REFERENCES
- 1.Dinesh Kumar M, Thirumavalavan N, Venugopal Krishna D, et al. QA of intensity-modulated beams using dynamic MLC log files. J Med Phys. 2006;31:36–41. doi: 10.4103/0971-6203.25668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lee J-W, Park J-H, Chung J-B, et al. Inverse verification of the dose distribution for intensity modulated radiation therapy patient-specific quality assurance using dynamic MLC log files. J Korean Phys Soc. 2009;55:1649–56. [Google Scholar]
- 3.Lee L, Le Q-T, Xing L. Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. Int J Radiat Oncol Biol Phys. 2008;70:634–44. doi: 10.1016/j.ijrobp.2007.09.054. [DOI] [PubMed] [Google Scholar]
- 4.Li JG, Dempsey JF, Ding L, et al. Validation of dynamic MLC-controller log files using a two-dimensional diode array. Med Phys. 2003;30:799–805. doi: 10.1118/1.1567951. [DOI] [PubMed] [Google Scholar]
- 5.Luo W, Li J, Price RA, Jr, et al. Monte Carlo based IMRT dose verification using MLC log files and R/V outputs. Med Phys. 2006;33:2557–64. doi: 10.1118/1.2208916. [DOI] [PubMed] [Google Scholar]
- 6.Mu G, Ludlum E, Xia P. Impact of MLC leaf position errors on simple and complex IMRT plans for head and neck cancer. Phys Med Biol. 2008;53:77–88. doi: 10.1088/0031-9155/53/1/005. [DOI] [PubMed] [Google Scholar]
- 7.Stell AM, Li JG, Zeidan OA, et al. An extensive log-file analysis of step-and-shoot intensity modulated radiation therapy segment delivery errors. Med Phys. 2004;31:1593–602. doi: 10.1118/1.1751011. [DOI] [PubMed] [Google Scholar]
- 8.Yan G, Liu C, Simon TA, et al. On the sensitivity of patient-specific IMRT QA to MLC positioning errors. J Appl Clin Med Phys. 2009;10:2915. doi: 10.1120/jacmp.v10i1.2915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Barrett A, Dobbs J, Morris S, et al. Prostate. In: Jamieson G, editor. Practical Radiotherapy Planning. 4th ed. London: Oxford University Press; 2009. pp. 332–50. [Google Scholar]
- 10.Ezzell GA, Galvin JM, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys. 2003;30:2089–115. doi: 10.1118/1.1591194. [DOI] [PubMed] [Google Scholar]
- 11.Sastre-Padro M, Welleweerd J, Malinen E, et al. Consequences of leaf calibration errors on IMRT delivery. Phys Med Biol. 2007;52:1147–56. doi: 10.1088/0031-9155/52/4/019. [DOI] [PubMed] [Google Scholar]
- 12.Venencia CD, Besa P. Commissioning and quality assurance for intensity modulated radiotherapy with dynamic multileaf collimator: experience of the Pontificia Universidad Catolica de Chile. J Appl Clin Med Phys. 2004;5:37–54. doi: 10.1120/jacmp.v5i3.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chow JC, Jiang R, Markel D. The effect of interfraction prostate motion on IMRT plans: a dose-volume histogram analysis using a Gaussian error function model. J Appl Clin Med Phys. 2009;10:3055. doi: 10.1120/jacmp.v10i4.3055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Orton NP, Tome WA. The impact of daily shifts on prostate IMRT dose distributions. Med Phys. 2004;31:2845–8. doi: 10.1118/1.1784592. [DOI] [PubMed] [Google Scholar]
- 15.Yoon M, Park S-Y, Shin D, et al. A new homogeneity index based on statistical analysis of the dose-volume histogram. J Appl Clin Med Phys. 2007;8:9–17. doi: 10.1120/jacmp.v8i2.2390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Feuvret L, Noel G, Mazeron JJ, et al. Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006;64:333–42. doi: 10.1016/j.ijrobp.2005.09.028. [DOI] [PubMed] [Google Scholar]
- 17.Low DA, Harms WB, Mutic S, et al. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25:656–61. doi: 10.1118/1.598248. [DOI] [PubMed] [Google Scholar]
- 18.Park CS, Kim Y, Lee N, et al. Method to account for dose fractionation in analysis of IMRT plans: modified equivalent uniform dose. Int J Radiat Oncol Biol Phys. 2005;62:925–32. doi: 10.1016/j.ijrobp.2004.11.039. [DOI] [PubMed] [Google Scholar]
- 19.Hoffmann AL, den Hertog D, Siem AY, et al. Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects. Phys Med Biol. 2008;53:6345–62. doi: 10.1088/0031-9155/53/22/006. [DOI] [PubMed] [Google Scholar]
- 20.Gay HA, Niemierko A. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med. 2007;23:115–5. doi: 10.1016/j.ejmp.2007.07.001. [DOI] [PubMed] [Google Scholar]
- 21.Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–5. doi: 10.1016/j.ijrobp.2004.04.014. [DOI] [PubMed] [Google Scholar]
- 22.Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–35. doi: 10.1016/0360-3016(91)90172-z. [DOI] [PubMed] [Google Scholar]
- 23.Buyyounouski MK, Horwitz EM, Price RA, Jr, et al. Prostate IMRT Image-guided IMRT. In: Bortfeld T, Schmidt-Ullrich R, De Neve W, et al., editors. Berlin: Springer; 2006. pp. 391–410. [Google Scholar]
- 24.Cheung R, Tucker SL, Lee AK, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:993–1002. doi: 10.1016/j.ijrobp.2004.07.723. [DOI] [PubMed] [Google Scholar]
- 25.Dasu A, Toma-Dasu I, Olofsson J, et al. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncol. 2005;44:339–47. doi: 10.1080/02841860510029833. [DOI] [PubMed] [Google Scholar]
- 26.Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22. doi: 10.1016/0360-3016(91)90171-y. [DOI] [PubMed] [Google Scholar]
- 27.Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:249–62. doi: 10.1080/09553009214552071. [DOI] [PubMed] [Google Scholar]
- 28.Niemierko A. Biological optimization Image-guided IMRT. In: Bortfeld T, Schmidt-Ullrich R, De Neve W, et al., editors. Berlin: Springer; 2006. pp. 199–216. [Google Scholar]
- 29.Kim Y, Tome WA. Optimization of radiotherapy using biological parameters. Radiation Oncology Advances. In: Bentzen SM, Harari PM, Tomé WA, et al., editors. New York: Springer; 2008. pp. 253–74. [Google Scholar]
- 30.Luxton G, Keall PJ, King CR. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD) Phys Med Biol. 2008;53:23–36. doi: 10.1088/0031-9155/53/1/002. [DOI] [PubMed] [Google Scholar]
- 31.Zaider M. The integral biologically effective dose (IBED) serves as an indicator of relative damage to an organ: plausible but incorrect. Int J Radiat Oncol Biol Phys. 1999;45:828–9. doi: 10.1016/s0360-3016(99)90413-3. [DOI] [PubMed] [Google Scholar]
- 32.Kim Y, Tome WA. On voxel based iso-tumor control probability and iso-complication maps for selective boosting and selective avoidance intensity modulated radiotherapy. Imaging Decis (Berl) 2008;12:42–50. doi: 10.1111/j.1617-0830.2008.00118.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76:S3–9. doi: 10.1016/j.ijrobp.2009.09.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Valdagni R, Rancati T, Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer. 2009;115:3141–9. doi: 10.1002/cncr.24356. [DOI] [PubMed] [Google Scholar]
- 35.Zhang M, Moiseenko V, Liu M, et al. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: result of organ motion simulations. Phys Med Biol. 2006;51:269–85. doi: 10.1088/0031-9155/51/2/006. [DOI] [PubMed] [Google Scholar]
- 36.Cheung R, Tucker SL, Ye J-S, et al. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1513–9. doi: 10.1016/j.ijrobp.2003.09.015. [DOI] [PubMed] [Google Scholar]
- 37.Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9. doi: 10.1016/j.ijrobp.2009.07.1754. [DOI] [PMC free article] [PubMed] [Google Scholar]